Cochrane · systematic review · CD009256
Cisplatin versus carboplatin in combination with third‐generation drugs for advanced non‐small cell lung cancer
Vasconcellos, VF, Marta, GN, da Silva, EMK, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Lung CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 50%High 3 · 50%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Carboplatin compared with cisplatin chemotherapy in combination with third‐generation drugs for advanced non‐small cell lung cancer
Population: combination with third‐generation drugs for advanced non‐small cell lung cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) Carboplatin vs cisplatin chemotherapy | HR 0.99 [0.82, 1.2] | 10 studies · 2515 participants | High |
1‐year survival rate Carboplatin vs cisplatin chemotherapy | RR 0.98 [0.89, 1.08] | 11 studies · 4004 participants | High |
Response rate Carboplatin vs cisplatin chemotherapy | RR 0.89 [0.79, 1] | 11 studies · 4020 participants | High |
Grade III or IV neurotoxicity Carboplatin vs cisplatin chemotherapy | RR 1.42 | 10 studies · 3857 participants | Moderate |
Grade III or IV thrombocytopenia Carboplatin vs cisplatin chemotherapy | RR 2.46 [1.49, 4.04] | 10 studies · 3857 participants | Moderate Downgraded: inconsistency |
Grade III or IV renal toxicity Carboplatin vs cisplatin chemotherapy | RR 0.52 [0.19, 1.45] | 3 studies · 1272 participants | Moderate |